Conclusion
SLE is different for every patient who has it, and ACE’s researchers are getting closer to understanding why and how. We look forward to a future when tailored therapies for SLE patients are reality. We may not be that far off.
Samantha C. Shapiro, MD, is the executive editor of Harrison’s Principles of Internal Medicine. As a clinician educator, she practices telerheumatology and writes for both medical and lay audiences.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
References
- National Institute of Allergy and Infectious Diseases (NIAID).
- Jenks SA, Cashman KS, Zumaquero E, et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity. 2018;49(4).
- Scharer CD, Blalock EL, Mi T, et al. Epigenetic programming underpins B cell dysfunction in human SLE. Nat Immunol. 2019;20(8).
- Woodruff MC, Ramonell RP, Haddad NS, et al. Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature. 2022;611(7934).
- Nehar-Belaid D, Hong S, Marches R, et al. Mapping systemic lupus erythematosus heterogeneity at the single-cell level. Nat Immunol. 2020;21(9).
- Caielli S, Veiga DT, Balasubramanian P, et al. A CD4+ T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate. Nat Med. 2019;25(1).
- Caielli S, Cardenas J, de Jesus AA, et al. Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE. Cell. 2021;184(17).
- Li H, Tsokos MG, Tsokos GC. Lymphocytes in the neighborhood: Good or bad for the kidney? J Clin Invest. 2022;132(13).
- Abraham R, Durkee MS, Ai J, et al. Specific in situ inflammatory states associate with progression to renal failure in lupus nephritis. J Clin Invest. 2022;132(13).
- Liarski VM, Sibley A, Panhuys N van, et al. TD-03 convolutional neural networks identify in situ adaptive immune cell architectures in human lupus. Lupus Science & Medicine. 2018;5:doi: 10.1136/lupus-2018-lsm.122
